CD28: T-cell-specific surface glycoprotein CD28
Receptor that plays a role in T-cell activation, proliferation, survival and the maintenance of immune homeostasis.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on CD28, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Other 1
| Lulizumab pegol | Phase 2 | Bristol-Myers Squibb | Antibody | AntagonistT-cell-specific surface glycoprotein CD28 antagonist | 0 |
| TGN-1412 | Phase 2 | Theramab LLC | Other | AgonistT-cell-specific surface glycoprotein CD28 agonist | 0 |
- HIV infectious disease0.51
- Asthma0.48
- Inflammatory bowel disease0.42
- Immunodeficiency 123 with HPV-related verrucosis0.40
- Cancer0.39
- Autoimmune disease0.37
- Hypothyroidism0.33
- Nephrotic syndrome0.33
- Sclerosing cholangitis0.32
- Tietze syndrome0.32
- Rheumatoid arthritis0.30
- Celiac disease0.30
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5191, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P10747, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets